A longitudinal study on quality of life along the spectrum of Alzheimer’s disease
Abstract Background Quality of life (QoL) is an important outcome from the perspective of patients and their caregivers, in both dementia and pre-dementia stages. Yet, little is known about the long-term changes in QoL over time. We aimed to compare the trajectories of QoL between amyloid-positive a...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-09-01
|
| Series: | Alzheimer’s Research & Therapy |
| Online Access: | https://doi.org/10.1186/s13195-022-01075-8 |
| _version_ | 1811267325997875200 |
|---|---|
| author | Arenda Mank Judith J. M. Rijnhart Ingrid S. van Maurik Linus Jönsson Ron Handels Els D. Bakker Charlotte E. Teunissen Bart N. M. van Berckel Argonde C. van Harten Johannes Berkhof Wiesje M. van der Flier |
| author_facet | Arenda Mank Judith J. M. Rijnhart Ingrid S. van Maurik Linus Jönsson Ron Handels Els D. Bakker Charlotte E. Teunissen Bart N. M. van Berckel Argonde C. van Harten Johannes Berkhof Wiesje M. van der Flier |
| author_sort | Arenda Mank |
| collection | DOAJ |
| description | Abstract Background Quality of life (QoL) is an important outcome from the perspective of patients and their caregivers, in both dementia and pre-dementia stages. Yet, little is known about the long-term changes in QoL over time. We aimed to compare the trajectories of QoL between amyloid-positive and amyloid-negative SCD or MCI patients and to evaluate QoL trajectories along the Alzheimer’s disease (AD) continuum of cognitively normal to dementia. Methods We included longitudinal data of 447 subjective cognitive decline (SCD), 276 mild cognitive impairment (MCI), and 417 AD dementia patients from the Amsterdam Dementia Cohort. We compared QoL trajectories (EQ-5D and visual analog scale (VAS)) between (1) amyloid-positive and amyloid-negative SCD or MCI patients and (2) amyloid-positive SCD, MCI, and dementia patients with linear mixed-effect models. The models were adjusted for age, sex, Charlson Comorbidity Index (CCI), education, and EQ-5D scale (3 or 5 level). Results In SCD, amyloid-positive participants had a higher VAS at baseline but showed a steeper decline over time in EQ-5D and VAS than amyloid-negative participants. Also, in MCI, amyloid-positive patients had higher QoL at baseline but subsequently showed a steeper decline in QoL over time compared to amyloid-negative patients. When we compared amyloid-positive patients along the Alzheimer continuum, we found no difference between SCD, MCI, or dementia in baseline QoL, but QoL decreased at a faster rate in the dementia stage compared with the of SCD and MCI stages. Conclusions QoL decreased at a faster rate over time in amyloid-positive SCD or MCI patients than amyloid-negative patients. QoL decreases over time along the entire AD continuum of SCD, MCI and dementia, with the strongest decrease in dementia patients. Knowledge of QoL trajectories is essential for the future evaluation of treatments in AD. |
| first_indexed | 2024-04-12T21:00:40Z |
| format | Article |
| id | doaj.art-9ae514995a574a0da9c50b37b218341a |
| institution | Directory Open Access Journal |
| issn | 1758-9193 |
| language | English |
| last_indexed | 2024-04-12T21:00:40Z |
| publishDate | 2022-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Alzheimer’s Research & Therapy |
| spelling | doaj.art-9ae514995a574a0da9c50b37b218341a2022-12-22T03:16:51ZengBMCAlzheimer’s Research & Therapy1758-91932022-09-0114111010.1186/s13195-022-01075-8A longitudinal study on quality of life along the spectrum of Alzheimer’s diseaseArenda Mank0Judith J. M. Rijnhart1Ingrid S. van Maurik2Linus Jönsson3Ron Handels4Els D. Bakker5Charlotte E. Teunissen6Bart N. M. van Berckel7Argonde C. van Harten8Johannes Berkhof9Wiesje M. van der Flier10Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmcAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Data Science, Amsterdam Public Health InstituteAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmcDepartment for Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska InstitutetDepartment for Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska InstitutetAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmcNeurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center Amsterdam, Amsterdam UMCAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmcAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmcAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Data Science, Amsterdam Public Health InstituteAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmcAbstract Background Quality of life (QoL) is an important outcome from the perspective of patients and their caregivers, in both dementia and pre-dementia stages. Yet, little is known about the long-term changes in QoL over time. We aimed to compare the trajectories of QoL between amyloid-positive and amyloid-negative SCD or MCI patients and to evaluate QoL trajectories along the Alzheimer’s disease (AD) continuum of cognitively normal to dementia. Methods We included longitudinal data of 447 subjective cognitive decline (SCD), 276 mild cognitive impairment (MCI), and 417 AD dementia patients from the Amsterdam Dementia Cohort. We compared QoL trajectories (EQ-5D and visual analog scale (VAS)) between (1) amyloid-positive and amyloid-negative SCD or MCI patients and (2) amyloid-positive SCD, MCI, and dementia patients with linear mixed-effect models. The models were adjusted for age, sex, Charlson Comorbidity Index (CCI), education, and EQ-5D scale (3 or 5 level). Results In SCD, amyloid-positive participants had a higher VAS at baseline but showed a steeper decline over time in EQ-5D and VAS than amyloid-negative participants. Also, in MCI, amyloid-positive patients had higher QoL at baseline but subsequently showed a steeper decline in QoL over time compared to amyloid-negative patients. When we compared amyloid-positive patients along the Alzheimer continuum, we found no difference between SCD, MCI, or dementia in baseline QoL, but QoL decreased at a faster rate in the dementia stage compared with the of SCD and MCI stages. Conclusions QoL decreased at a faster rate over time in amyloid-positive SCD or MCI patients than amyloid-negative patients. QoL decreases over time along the entire AD continuum of SCD, MCI and dementia, with the strongest decrease in dementia patients. Knowledge of QoL trajectories is essential for the future evaluation of treatments in AD.https://doi.org/10.1186/s13195-022-01075-8 |
| spellingShingle | Arenda Mank Judith J. M. Rijnhart Ingrid S. van Maurik Linus Jönsson Ron Handels Els D. Bakker Charlotte E. Teunissen Bart N. M. van Berckel Argonde C. van Harten Johannes Berkhof Wiesje M. van der Flier A longitudinal study on quality of life along the spectrum of Alzheimer’s disease Alzheimer’s Research & Therapy |
| title | A longitudinal study on quality of life along the spectrum of Alzheimer’s disease |
| title_full | A longitudinal study on quality of life along the spectrum of Alzheimer’s disease |
| title_fullStr | A longitudinal study on quality of life along the spectrum of Alzheimer’s disease |
| title_full_unstemmed | A longitudinal study on quality of life along the spectrum of Alzheimer’s disease |
| title_short | A longitudinal study on quality of life along the spectrum of Alzheimer’s disease |
| title_sort | longitudinal study on quality of life along the spectrum of alzheimer s disease |
| url | https://doi.org/10.1186/s13195-022-01075-8 |
| work_keys_str_mv | AT arendamank alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT judithjmrijnhart alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT ingridsvanmaurik alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT linusjonsson alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT ronhandels alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT elsdbakker alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT charlotteeteunissen alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT bartnmvanberckel alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT argondecvanharten alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT johannesberkhof alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT wiesjemvanderflier alongitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT arendamank longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT judithjmrijnhart longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT ingridsvanmaurik longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT linusjonsson longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT ronhandels longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT elsdbakker longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT charlotteeteunissen longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT bartnmvanberckel longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT argondecvanharten longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT johannesberkhof longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease AT wiesjemvanderflier longitudinalstudyonqualityoflifealongthespectrumofalzheimersdisease |